Sweden · Delayed Price · Currency is SEK Hansa Biopharma AB Statistics
Total Valuation
STO:HNSA has a market cap or net worth of SEK 3.51 billion. The enterprise value is 3.97 billion.
| Market Cap | 3.51B |
| Enterprise Value | 3.97B |
Important Dates
The next confirmed earnings date is Wednesday, July 22, 2026.
| Earnings Date | Jul 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:HNSA has 101.76 million shares outstanding. The number of shares has increased by 34.63% in one year.
| Current Share Class | 101.76M |
| Shares Outstanding | 101.76M |
| Shares Change (YoY) | +34.63% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.12% |
| Owned by Institutions (%) | 22.16% |
| Float | 72.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 91.34 |
| PS Ratio | 18.42 |
| PB Ratio | -12.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.63
| Current Ratio | 3.63 |
| Quick Ratio | 3.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -38.17% |
| Return on Invested Capital (ROIC) | -56.51% |
| Return on Capital Employed (ROCE) | -60.45% |
| Weighted Average Cost of Capital (WACC) | 13.52% |
| Revenue Per Employee | 1.56M |
| Profits Per Employee | -5.67M |
| Employee Count | 122 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 17.20 |
Taxes
In the past 12 months, STO:HNSA has paid 2.38 million in taxes.
| Income Tax | 2.38M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.51% in the last 52 weeks. The beta is 1.57, so STO:HNSA's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | +32.51% |
| 50-Day Moving Average | 30.33 |
| 200-Day Moving Average | 32.29 |
| Relative Strength Index (RSI) | 62.28 |
| Average Volume (20 Days) | 572,465 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:HNSA had revenue of SEK 190.49 million and -691.58 million in losses. Loss per share was -7.71.
| Revenue | 190.49M |
| Gross Profit | 113.66M |
| Operating Income | -570.27M |
| Pretax Income | -689.20M |
| Net Income | -691.58M |
| EBITDA | -567.78M |
| EBIT | -570.27M |
| Loss Per Share | -7.71 |
Balance Sheet
The company has 676.46 million in cash and 1.14 billion in debt, with a net cash position of -465.80 million or -4.58 per share.
| Cash & Cash Equivalents | 676.46M |
| Total Debt | 1.14B |
| Net Cash | -465.80M |
| Net Cash Per Share | -4.58 |
| Equity (Book Value) | -275.27M |
| Book Value Per Share | -2.70 |
| Working Capital | 575.46M |
Cash Flow
| Operating Cash Flow | -554.28M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.49M |
| Net Borrowing | 116.16M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 59.67% |
| Operating Margin | -299.37% |
| Pretax Margin | -361.81% |
| Profit Margin | n/a |
| EBITDA Margin | -298.07% |
| EBIT Margin | -299.37% |
| FCF Margin | n/a |
Dividends & Yields
STO:HNSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.63% |
| Shareholder Yield | -34.63% |
| Earnings Yield | -19.71% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for STO:HNSA is 75.71, which is 119.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 75.71 |
| Price Target Difference | 119.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 62.39% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |